Cystatin B and its EPM1 mutants are polymeric and aggregate prone in vivo

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1783, Issue 2, 2008, Pages 312-322

  Cipollini, Elena ^a   Riccio, Massimo ^b   Di Giaimo, Rossella ^c   Dal Piaz, Fabrizio ^d   Pulice, Giuseppe ^a   Catania, Sandra ^a   Caldarelli, Ilaria ^c   Dembic, Maja ^e   Santi, Spartaco ^e   Melli, Marialuisa ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

^e RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Cellular aggregates; Cystatin B; Cytoskeleton; EPM1; Neurodegeneration; Polymers

Indexed keywords

CYSTATIN B; CYSTEINE; DIMER; DODECYL SULFATE SODIUM; HYDROGEN PEROXIDE; MONOMER; POLYMER; UREA;

ALKALINITY; ANIMAL CELL; ARTICLE; CELL AGGREGATION; CELL CULTURE; CELL INCLUSION; CHEMICAL STRUCTURE; CYTOPLASM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MASS SPECTROMETRY; MOLECULAR WEIGHT; MUTANT; MYOCLONUS EPILEPSY; NERVE DEGENERATION; NEUROBLASTOMA CELL; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN STRUCTURE; RAT; WILD TYPE;

ANIMALS; CELL LINE; CHROMATOGRAPHY, GEL; CYSTATINS; CYSTEINE; HUMANS; HYDROGEN-ION CONCENTRATION; MASS SPECTROMETRY; MICROSCOPY, ELECTRON; MUTANT PROTEINS; MYOCLONIC EPILEPSIES, PROGRESSIVE; OXIDANTS; PROTEIN STRUCTURE, QUATERNARY; RATS; RECOMBINANT FUSION PROTEINS; REDUCING AGENTS; TIME FACTORS; TRANSFECTION;

EID: 38349087503     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2007.08.007     Document Type: Article

References (60)

1. Barret A.J., and Kirschke H. Cystatin, the egg white inhibitor of cysteine proteinases. Methods Enzymol. 80 (1981) 771
2. Jarvinen M., and Rinne A. Human spleen cysteine proteinase inhibitor. Purification, fractionation into isoelectric variants and some properties of the variants. Biochim. Biophys. Acta 708 (1982) 210
3. Turk V., and Bode W. The cystatins: proteins inhibitors of cysteine proteinases. FEBS Lett. 285 (1991) 213
4. Rawlings N.D., and Barrett A.J. Evolution of proteins of the cystatin superfamily. J. Mol. Evol. 30 (1990) 60-71
5. Brown W.M., and Dziegielewska K.M. Friends and relations of the cystatin superfamily-new members and their evolution. Protein Sci. 6 (1997) 5-12
6. Lehesjoki A.E. Molecular background of progressive myoclonus epilepsy. EMBO J. 22 (2003) 3473-3478
7. Stubbs M., Laber B., Bode W., Huber R., Jerala R., Lenarcic B., and Turk V. The refined 2.4A X-ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. EMBO J. 9 (1990) 1939-1947
8. Janowski R., Kozak M., Jankowska E., Grzonka Z., Grubb A., Abrahamson M., and Jaskolski M. Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nat. Struct. Biol. 8 (2001) 316-320
9. Jenko Kokalj S., Guncar G., Stern I., Morgan G., Rabzelj S., Kenig M., Staniforth R.A., Waltho J.P., Zerovnik E., and Turk D. Essential role of proline isomerization in stefin B tetramer formation. J. Mol. Biol. 9 (2007) 1569-1579
10. Di Giaimo R., Riccio M., Santi S., Galeotti C., Ambrosetti D.C., and Melli M. New insights into the molecular basis of progressive myoclonus epilepsy (EPM1): a multiprotein complex with cystatin B. Hum. Mol. Genet. 11 (2002) 2941-2950
11. Riccio M., Santi S., Dembic M., Di Giaimo R., Cipollini E., Costantino-Ceccarini E., Ambrosetti D.C., Maraldi N.M., and Melli M. Cell-specific expression of the epm1 (cystatin B) gene in developing rat cerebellum. Neurobiol. Dis. 20 (2005) 104-114
12. Keppler D. Towards novel anti-cancer strategies based on cystatin functions. Cancer Lett. 235 (2006) 159-176
13. Bobek L.A., and Levine M.J. Cystatins-inhibitors of cysteine proteinases. Crit. Rev. Oral Biol. Med. 3 (1987) 307-332
14. Lefebvre C., Cocquerelle C., Vandenbulcke F., Hot D., Huot L., Lemoine L., and Salzet M. Transcriptomic analysis in the leech Theromyzon tessulatum: involvement of cystatin B in innate immunity. Biochem. J. 380 (2004) 617-625
15. Ii K., Ito H., Kominami E., and Hirano A. Abnormal distribution of cathepsin proteinases and endogenous inhibitors (cystatins) in the hippocampus of patients with Alzheimer's disease, parkinsonism-dementia complex on Guam, and senile dementia and in the aged. Virchows Arch., A Pathol. Anat. Histopathol. 423 (1993) 185-194
16. Suzuki T., Hashimoto S., Toyoda N., Nagai S., Yamazaki N., Dong H.Y., Sakai J., Yamashita T., Nukiwa T., and Matsushima K. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood 96 (2000) 2584-2591
17. Zerovnik E., Pompe-Novak M., Skarabot M., Ravnikar M., Musevic I., and Turk V. Human stefin B readily forms amyloid fibrils in vitro. Biochim. Biophys. Acta 1594 (2002) 1-5
18. Jenko S., Skarabot M., Kenig M., Guncar G., Musevic I., Turk D., and Zerovnik E. Different propensity to form amyloid fibrils by two homologous proteins-human stefins A and B: searching for an explanation. Proteins 55 (2004) 417-425
19. Nilsson M.R. Techniques to study amyloid fibril formation in vitro. Methods 34 (2004) 151-160
20. Staniforth R.A., Giannini S., Higgins L.D., Conroy M.J., Hounslow A.M., Jerala R., Craven C.J., and Waltho J.P. Three-dimensional domain swapping in the folded and molten-globule states of cystatins, an amyloid-forming structural superfamily. EMBO J. 20 (2001) 4774-4781
21. Sanders A., Jeremy Craven C., Higgins L.D., Giannini S., Conroy M.J., Hounslow A.M., Waltho J.P., and Staniforth R.A. Cystatin forms a tetramer through structural rearrangement of domain-swapped dimers prior to amyloidogenesis. J. Mol. Biol. 336 (2004) 165-178
22. Genton P. Unverricht-Lundborg disease (PME1). Rev. Neurol. (Paris) 162 (2006) 819-826
23. Eldridge R., Iivanainen M., Stern R., Koerber T., and Wilderý` B.J. 'Baltic' myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet 8 (1983) 838-842
24. Berkovic S.F., Mazarib A., Walid S., Neufeld M.Y., Manelis J., Nevo Y., Korczyn A.D., Yin J., Xiong L., Pandolfo M., Mulley J.C., and Wallace R.H. A new clinical and molecular form of Unverricht-Lundborg disease localized by homozygosity mapping. Brain 128 (2005) 652-658
25. Coppola G., Criscuolo C., De Michele G., Striano S., Barbieri F., Striano P., Perretti A., Santoro L., Brescia Morra V., Sacca F., Scarano V., D'A damo A.P., Banfi S., Gasparini P., Santorelli F.M., Lehesjoki A.E., and Filla A. Autosomal recessive progressive myoclonus epilepsy with ataxia and mental retardation. J. Neurol. 252 (2005) 897-900
26. Lafreniere R., Rochefort D., Chrretien N., Rommens J., Cochius J., Kalviainen R., Nousiainen U., Patry G., Farrel K., Soderfeldt B., Federico A., Hale B., Cossio O., Soresen T., Pouliot M., Kmiec T., Uldal P., Janszky J., Pranzatelli M., Andermann F., Anderman E., and Rouleau G. Unstable insertion in the 5' flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPM1. Nat. Genet. 15 (1997) 298-302
27. Virtaneva K., D'Amato E., Miao J., Koskiniemi M., Norio R., Avanzini G., Franceschetti S., Michelucci R., Tassinari C.A., Omer S., Pennacchio L.A., Myers R.M., Dieguez-Lucena J.L., Krahe R., de la Chapelle A., and Lehesjoki A.E. Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. Nat. Genet. 15 (1997) 393-396
28. Alakurtti K., Weber E., Rinne R., Theil G., de Haan G.J., Lindhout D., Salmikangas P., Saukko P., Lahtinen U., and Lehesjoki A.E. Loss of lysosomal association of cystatin B proteins representing progressive myoclonus epilepsy, EPM1, mutations. Eur. J. Hum. Genet. 13 (2005) 208-215
29. Riccio M., Dembic M., Cinti C., and Santi S. Multifluorescence labeling and colocalization analysis. Methods Mol. Biol. 285 (2004) 171-177
30. Zerovnik E., Jerala R., Kroon-Zitko L., Pain R.H., and Turk V. Intermediates in denaturation of a small globular protein, recombinant human stefin B. J. Biol Chem. 267 (1992) 9041-9046
31. Zerovnik E., Jerala R., Kroon-Zitko L., Turk V., and Lohner K. Characterization of the equilibrium intermediates in acid denaturation of human stefin B. Eur. J. Biochem. 245 (1997) 364-372
32. Kim S.O., Merchant K., Nudelman R., Beyer Jr. W.F., Keng T., De Angelo J., Hausladen A., and Stamler J.S. OxyR: a molecular code for redox-related signaling. Cell 109 (2002) 383-396
33. Ghezzi P., and Bonetto V. Redox proteomics: identification of oxidatively modified proteins. Proteomics 3 (2003) 1145-1153
34. Levy E., Jaskolski M., and Grubb A. The role of cystatin C in cerebral amyloid angiopathy and stroke: cell biology and animal models. Brain Pathol. 16 (2006) 60-70
35. Rabzelj S., Turk V., and Zerovnik E. In vitro study of stability and amyloid-fibril formation of two mutants of human stefin B (cystatin B) occurring in patients with EPM1. Protein Sci. 14 (2005) 2713-2722
36. Muchowski P.J., and Wacker J.L. Modulation of neurodegeneration by molecular chaperones. Nat. Rev., Neurosci. 6 (2005) 11-22
37. Di Giaimo R., Pianetti S., Calmieri P.P., Melli M., and Santi S. Nuclear localization of cystatin B, the cathepsin inhibitor implicated in myoclonous epilepsy (EPM1). Exp. Cell Res. 262 (2001) 84-94
38. Speransky V.V., Taylor K.L., Edskes H.K., Wickner R.B., and Steven A.C. Prion filament networks in [URE3] cells of Saccharomyces cerevisiae. J. Cell Biol. 153 (2001) 1327-1336
39. Manning M., and Colòn W. Structural basis of protein kinetic stability: resistance to sodium dodecyl sulfate suggests a central role for rigidity and a bias toward beta-sheet structure. Biochemistry 43 (2004) 11248-11254
40. Zerovnik E., Skerget K., Tusek-Znidaric M., Loeschner C., Brazier M.W., and Brown D.R. High affinity copper binding by stefin B (cystatin B) and its role in the inhibition of amyloid fibrillation. FEBS J. 273 (2006) 4250-4263
41. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., and Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
42. Walsh D.M., Townsend M., Podlisn M.B., Shanka G.M., Fadeev J.V., Agnaf O.E., Hartley D.M., and Selkoe D.J. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J. Neurosci. 25 (2005) 2455-2462
43. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., and Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440 (2006) 352-357
44. Knaus K.J., Morillas M., Swietnicki W., Malone M., Surewicz W.K., and Yee V.C. Crystal structure of the human prion protein reveals a mechanism for oligomerization. Nat. Struct. Biol. 8 (2001) 770-774
45. Janowski R., Abrahamson M., Grubb A., and Jaskolski M. Domain swapping in N-truncated human cystatin C. J. Mol. Biol. 341 (2004) 151-160
46. Nilsson M., Wang X., Rodziewicz-Motowidlo S., Janowski R., Lindstrom V., Onnerfjord P., Westermark G., Grzonka Z., Jaskolski M., and Grubb A. Prevention of domain swapping inhibits dimerization and amyloid fibril formation of cystatin C: use of engineered disulfide bridges, antibodies, and carboxymethylpapain to stabilize the monomeric form of cystatin C. J. Biol. Chem. 279 (2004) 24236-24245
47. Wahlbom M., Wang X., Lindström V., Carlemalm E., Jaskolski M., and Grubb A. Fibrillogenic oligomers of human cystatin c are formed by propagated domain swapping. J. Biol. Chem. 282 25 (June 22 2007) 18318-18326
48. Harris D.A., and True H.L. New insights into prion structure and toxicity. Neuron 50 (2006) 353-357
49. Rajan R.S., Illing M.E., Bence N.F., and Kopito R.R. Specificity in intracellular protein aggregation and inclusion body formation. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13060-13065
50. Kopito R.R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 10 (2000) 524-530
51. Houseweart M.K., Pennacchio L.A., Vilaythong A., Peters C., Noebels J.L., and Myers R.M. Cathepsin B but not cathepsins L or S contributes to the pathogenesis of Unverricht-Lundborg progressive myoclonus epilepsy (EPM1). J. Neurobiol. 56 (2003) 315-327
52. Franceschetti S., Sancini G., Buzzi A., Zucchini S., Paradiso B., Magnaghi G., Frassoni C., Chikhladze M., Avanzini G., and Simonato M. A pathogenetic hypothesis of Unverricht-Lundborg disease onset and progression. Neurobiol. Dis. 25 (2006) 675-685
53. Collins S.R., Douglass A., Vale R.D., and Weissman J.S. Mechanism of prion propagation: amyloid growth occurs by monomer addition. PLoS Biol. 2 (2004) 1582-1590
54. Dobson C.M. Protein folding and misfolding. Nature 426 (2003) 884-890
55. Lindquist S. Mad cows meet psichotic yeast: the expansion of the prion hypothesis. Cell 89 (1997) 495-498
56. Tuite M.F., and Cox B.S. Propagation of yeast prions. Nat. Rev., Mol. Cell. Biol. 4 (2003) 878-890
57. Berson J.F., Theos A.C., Harper D.C., Tenza D., Raposo G., and Marks M.S. Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis. J. Cell Biol. 161 (2003) 521-533
58. Chapman M.R., Robinson L.S., Pinkner J.S., Roth R., Heuser J., Hammar M., Normark S., and Hultgren S.J. Role of Escherichia coli curli operons in directing amyloid fiber formation. Science 295 (2002) 851-855
59. Kelly J.W., and Balch W.E. Amyloid as a natural product. J. Cell Biol. 12 (2003) 461-462
60. Ceru S., Rabzelj S., Kopitar-Jerala N., Turk V., and Zerovnik E. Protein aggregation as a possible cause for pathology in a subset of familial Unverricht-Lundborg disease. Med. Hypotheses 64 (2005) 955